--- title: "Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Earnings Results" type: "News" locale: "en" url: "https://longbridge.com/en/news/285819778.md" description: "Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly earnings of ($0.42) EPS, missing analysts' estimates of ($0.41) by $0.01. This is an improvement from last year's ($0.56) EPS. The stock traded down 1.1% to $3.63, with a market cap of $396.11 million. Analysts have mixed ratings, with target prices ranging from $3.00 to $11.54. Insider trading activity included sales by General Counsel Martin Wilson and CEO Gaurav Shah. Institutional investors have increased their holdings significantly in recent months." datetime: "2026-05-09T18:45:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285819778.md) - [en](https://longbridge.com/en/news/285819778.md) - [zh-HK](https://longbridge.com/zh-HK/news/285819778.md) --- # Rocket Pharmaceuticals (NASDAQ:RCKT) Announces Earnings Results Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by ($0.01), Zacks reports. During the same quarter in the prior year, the business earned ($0.56) EPS. Get **Rocket Pharmaceuticals** alerts: ## Rocket Pharmaceuticals Trading Down 1.1% - 3 Small-Cap Stocks That Are Ready to Rocket Higher RCKT stock traded down $0.04 during mid-day trading on Friday, reaching $3.63. 3,682,797 shares of the stock traded hands, compared to its average volume of 2,125,075. Rocket Pharmaceuticals has a 52-week low of $2.19 and a 52-week high of $7.39. The stock's fifty day moving average is $4.09 and its 200-day moving average is $3.69. The company has a market cap of $396.11 million, a P/E ratio of -1.94 and a beta of 0.52. The company has a current ratio of 6.38, a quick ratio of 6.38 and a debt-to-equity ratio of 0.07. ## Wall Street Analyst Weigh In A number of analysts recently commented on RCKT shares. Cantor Fitzgerald boosted their target price on shares of Rocket Pharmaceuticals from $8.00 to $10.00 and gave the stock an "overweight" rating in a report on Friday, February 27th. The Goldman Sachs Group raised their target price on shares of Rocket Pharmaceuticals to $3.00 and gave the stock a "sell" rating in a report on Monday, March 2nd. Bank of America lifted their price target on shares of Rocket Pharmaceuticals from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Monday, March 30th. Wall Street Zen cut Rocket Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Sunday, March 8th. Finally, Lifesci Capital upgraded Rocket Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Rocket Pharmaceuticals presently has a consensus rating of "Hold" and an average target price of $11.54. **Read Our Latest Report on Rocket Pharmaceuticals** ## Insider Activity at Rocket Pharmaceuticals In other news, General Counsel Martin Wilson sold 12,253 shares of the business's stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,557.43. Following the sale, the general counsel owned 683,376 shares in the company, valued at $2,261,974.56. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Gaurav Shah sold 12,279 shares of the company's stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $3.31, for a total transaction of $40,643.49. Following the completion of the sale, the chief executive officer owned 1,052,045 shares of the company's stock, valued at approximately $3,482,268.95. This trade represents a 1.15% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 29,415 shares of company stock worth $97,398. 21.30% of the stock is currently owned by insiders. ## Institutional Trading of Rocket Pharmaceuticals Hedge funds and other institutional investors have recently modified their holdings of the business. MPM Bioimpact LLC raised its position in Rocket Pharmaceuticals by 141.2% during the second quarter. MPM Bioimpact LLC now owns 3,903,081 shares of the biotechnology company's stock valued at $9,563,000 after buying an additional 2,284,816 shares during the period. Qube Research & Technologies Ltd grew its stake in Rocket Pharmaceuticals by 690.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,548,262 shares of the biotechnology company's stock valued at $3,793,000 after acquiring an additional 1,352,469 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Rocket Pharmaceuticals by 52.0% in the 3rd quarter. Millennium Management LLC now owns 3,570,391 shares of the biotechnology company's stock valued at $11,639,000 after purchasing an additional 1,221,554 shares during the period. Opaleye Management Inc. acquired a new position in shares of Rocket Pharmaceuticals in the 4th quarter valued at about $3,352,000. Finally, JPMorgan Chase & Co. lifted its position in shares of Rocket Pharmaceuticals by 73.6% in the third quarter. JPMorgan Chase & Co. now owns 2,097,033 shares of the biotechnology company's stock worth $6,836,000 after purchasing an additional 889,231 shares in the last quarter. Institutional investors and hedge funds own 98.39% of the company's stock. ## Rocket Pharmaceuticals Company Profile (Get Free Report) Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms. The company's pipeline comprises multiple product candidates in various stages of development. ## Featured Articles - Five stocks we like better than Rocket Pharmaceuticals - Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due - Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches - Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money - Water Infrastructure: Why This Boring Sector Could Get Exciting _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Rocket Pharmaceuticals Right Now? Before you consider Rocket Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rocket Pharmaceuticals wasn't on the list. While Rocket Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [RCKT.US](https://longbridge.com/en/quote/RCKT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [RCKTW.US](https://longbridge.com/en/quote/RCKTW.US.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) ## Related News & Research - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md) - [Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition](https://longbridge.com/en/news/286608288.md) - [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md) - [Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data](https://longbridge.com/en/news/286407513.md)